{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:3703170d-b339-46d9-9b5f-f78d24b28fcc", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-10-08T04:04:59.724615Z", "firstcreated": "2026-10-08T04:01:47.425028Z", "pubstatus": "usable", "urgency": 5, "language": "uk", "headline": "Семаглутид пов'язують зі зниженням ризику хвороби Альцгеймера — дослідження", "byline": "Дарина Кравченко", "located": "Ukraine", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Контрактова", "usageterms": "Subscribers may republish this item in full, including translation and trimming, with the credit “Wireva / Контрактова”. Set rel=canonical to https://kontraktova.com/tekhnologii/semaglutid-pov-iazuiut-zi-znizhenniam-riziku-khvorobi-altsgeimera-doslidzhennia/ when publishing on the web.", "description_text": "Дослідження Case Western Reserve School of Medicine на майже мільйоні американців із діабетом 2 типу виявило, що пацієнти на семаглутиді (Ozempic, Wegovy) мали на 40–70% нижчий ризик першого діагнозу хвороби Альцгеймера порівняно з іншими цукрознижувальними препаратами. Дослідники наголошують: це лише зв'язок, а не доведена причинність, і потрібні подальші дослідження.", "altids": {"mosaic": "3703170d-b339-46d9-9b5f-f78d24b28fcc", "story": "ed5defbd-fcd5-4c4a-805b-9a0dc1b298d7", "slug": "semaglutid-pov-iazuiut-zi-znizhenniam-riziku-khvorobi-altsgeimera-doslidzhennia"}, "subject": [{"name": "Economy and business", "rel": "direct", "literal": "economy", "code": "medtop:04000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/04000000"}], "place": [{"name": "Ukraine", "literal": "ua", "code": "UA", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:dadbb151-ad87-4656-9ab9-b1411a02d64d", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says", "description_text": "Семаглутид пов'язують зі зниженням ризику хвороби Альцгеймера — дослідження", "copyrightholder": "fortune.com", "copyrightnotice": "Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says", "usageterms": "Picture belongs to the source publication: address and terms are delivered, the file is not.", "altids": {"wireva": "dadbb151-ad87-4656-9ab9-b1411a02d64d"}, "extra": {"wireva:delivery_mode": "link_only", "wireva:rights": {"licence": "", "licence_url": "", "licence_raw": "RSS source", "licence_verified_at": "2026-10-08T04:04:59.737766Z", "attribution_required": true, "attribution_text": "Drugs like Ozempic and Wegovy are linked to a lower risk of Alzheimer’s disease, new study says", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "fortune.com", "source_url": "https://fortune.com/img-assets/wp-content/uploads/2024/10/GettyImages-2152142563-e1729717350627.jpg?w=2048", "source_page_url": "https://fortune.com/img-assets/wp-content/uploads/2024/10/GettyImages-2152142563-e1729717350627.jpg?w=2048", "our_page_url": "https://kontraktova.com/tekhnologii/semaglutid-pov-iazuiut-zi-znizhenniam-riziku-khvorobi-altsgeimera-doslidzhennia/"}, "wireva:role": "lead"}, "renditions": {"source": {"href": "https://fortune.com/img-assets/wp-content/uploads/2024/10/GettyImages-2152142563-e1729717350627.jpg?w=2048", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:ed5defbd-fcd5-4c4a-805b-9a0dc1b298d7", "slug": "1056-20261007", "status": "updated", "languages": ["en", "uk"], "item_count": 4, "is_breaking": false}, "wireva:rights": {"class": "agency_original", "redistribution_allowed": true, "commercial_use_allowed": true, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Контрактова", "canonical_required": true, "canonical_url": "https://kontraktova.com/tekhnologii/semaglutid-pov-iazuiut-zi-znizhenniam-riziku-khvorobi-altsgeimera-doslidzhennia/", "linkback_required": true, "licence": "Wireva subscriber licence", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 0, "decided_by_rule": "agency_original_verified", "needs_review": false}, "wireva:provenance": {"production_method": "automated", "ai_stages": {"editing": true, "drafting": true, "headline": true, "discovery": true, "classification": true, "image_selection": true, "source_collection": true, "cross_source_comparison": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "multi_source", "independent_confirmations": 1, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "Матеріал підготовлено за допомогою ШІ під редакційною відповідальністю Haydamax OÜ.", "independence_check": {"status": "passed", "score": 0.079, "checked_at": "2026-10-08T04:04:59.735225Z"}}, "wireva:publication": {"name": "Контрактова", "domain": "kontraktova.com", "country": "UA", "url": "https://kontraktova.com/tekhnologii/semaglutid-pov-iazuiut-zi-znizhenniam-riziku-khvorobi-altsgeimera-doslidzhennia/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/3703170d-b339-46d9-9b5f-f78d24b28fcc", "html": "https://wireva.mib.news/item/3703170d-b339-46d9-9b5f-f78d24b28fcc/semaglutid-pov-iazuiut-zi-znizhenniam-riziku-khvorobi-altsgeimera-doslidzhennia/", "story": "https://wireva.mib.news/story/1056-20261007/"}, "wireva:metrics": {"word_count": 410, "char_count": 3190, "reading_time_seconds": 228}}}